The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 62.50
Bid: 60.00
Ask: 65.00
Change: 0.00 (0.00%)
Spread: 5.00 (8.333%)
Open: 62.50
High: 62.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

NetScientific Forms New Digital Health Company

1 May 2015 07:00

RNS Number : 9480L
NetScientific PLC
01 May 2015
 

NetScientific plc

("NetScientific" or the "Group")

 

NetScientific forms digital health company withUS hospital group, Meridian Health

 

Triventis Health LLC will commercialiseadvanced patient management solutions

 

1 May 2015: NetScientific (AIM: NSCI), the biomedical and healthcare technology group, has formed a new digital health sales and marketing subsidiary company, Triventis Health LLC ("Triventis") in partnership with iMPak Health, LLC ("iMPak"), a wholly owned subsidiary of Meridian Health Hospital Group, New Jersey, USA.

 

Triventis will provide smart digital healthcare solutions, enabling better patient data collection, connectivity and software to give healthcare providers actionable clinical data.

 

The new company will have its own sales force to sell and market the integrated solutions provided by a combination of Wanda Health's (a NetScientific subsidiary) cloud-based information analytics and iMPak's healthcare expertise and innovative easy-to-use medical devices, to intelligently monitor and manage patients.

 

This unique healthcare management product has undergone trial and will be adopted by the Meridian Hospital Group - which consists of six hospitals, 100 facility locations and generates US$1.6 billion in revenue. The product will then roll out across the USA to other healthcare providers.

 

The initial product provides continuous monitoring and assessment of patients with Congestive Heart Failure (CHF). Triventis will distribute other Wanda Health applications, notably for patients with co-morbidities and iMPak's next generation medication management to help improve compliance with prescription schedules.

 

Sir Richard Sykes, Chairman of NetScientific, said: "Keeping patients with chronic diseases out of hospital and managed in their homes is of critical importance to all hospital groups and providers worldwide. Our new partnership in the USA with Meridian Health and iMPak, working with Wanda Health analytics, will demonstrate how our combined expertise and technologies can improve patient well-being and reduce costs for providers."

 

Sal Inciardi, Senior Vice President of Business Development, Meridian Heath, said: "Triventis Health is dedicated to significantly enhancing how medical care is delivered. By integrating two key capabilities - healthcare solutions, and health information compilation and analytics - the company's products and services help healthcare practitioners make timely, more effective treatment decisions and improve outcomes for individuals living with a range of chronic diseases. We believe that we are uniquely positioned to enable customers to reduce the cost of healthcare associated with managing chronic disease, addressing what may be the greatest burden faced by most health systems around the world today."

 

-Ends-

 

Notes to Editors

About NetScientific

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment. For more information, please visit the website at www.NetScientific.net

About Wanda Health

 

Wanda Health is developing cloud-based analytics, as part of a total patient management solution, in partnership with other healthcare providers. The core analytics engine is based on 12 years of research at the Wireless Health Institute at UCLA. Wanda Health has completed development of a predictive analytics engine for use in remotely monitoring patients with Congestive Heart Failure, the leading cause of hospital re-admissions in USA.

 

About iMPak Health

(A wholly owned subsidiary of Meridian Health)

 

iMPak Health's mission is to develop innovative, easy-to-use devices to screen, diagnose and monitor health conditions through wireless technology. iMPak Health believes in the power of the individual. Their low cost, easy to use mobile health solutions are designed to help individuals assess, track and manage a variety of health conditions including cardiac health, COPD, diabetes, weight, asthma and others. The data collected can easily be shared with their physician for a complete personal health management solution. For more information about iMPak Health, visit www.impakhealth.com.

 

About Meridian Health

Meridian Health is a leading not-for-profit healthcare organization in New Jersey, comprising six hospitals and Meridian Partner Companies that include home health services, skilled nursing and rehabilitation centers, ambulatory care, ambulance services, fitness and wellness centers, and outpatient centers. With more than 100 convenient locations, over 1,800 beds, nearly 13,000 team members, and affiliations with more than 2,000 of the area's finest physicians, Meridian Health is a leading health care provider in New Jersey, providing quality health services, facilities, and programs. In September 2014, Meridian Health and Raritan Bay Medical Center signed a Letter of Intent to merge. In October 2014, Meridian Health and Hackensack University Health Network signed a Memorandum of Understanding to merge. For more information, please visit www.MeridianHealth.com.

 

NetScientific

Peter Thoms, CFO

Tel: +44 (0)77 2055 5752

Investec

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSDMFUSFISEIL
Date   Source Headline
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update
14th Nov 20222:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.